AURKA Primary Antibody
|Aliases||AIK; ARK1; AURA; BTAK; STK6; STK7; STK15; AURORA2; MGC34538; AURKA|
|Formulation||Ascitic fluid containing 0.03% sodium azide. |
|Immunogen||Purified recombinant fragment of human AURKA expressed in E. Coli.|
|Shipping Information||This product will ship in a box containing blue ice at a temperature of 4°C. Learn More|
|Species Reactivity||Human, Monkey, Rat|
|ICC (Immunocytochemistry)||1/200 - 1/1000|
|FCM (Flow Cytometry)||1/200 - 1/400|
|WB (Western Blot)||1/500 - 1/2000|
Contact us to order
Figure 1: Western blot analysis using AURKA mouse mAb against HEK293 (1), Sw620 (2), MCF-7 (3), Jurkat (4), Hela (5), HepG2 (6), Cos7 (7) and PC-12 (8) cell lysate.
Figure 2: Immunofluorescence analysis of Hela cells using AURKA mouse mAb (green). Blue: DRAQ5 fluorescent DNA dye.
Figure 3: Flow cytometric analysis of K562 cells using AURKA mouse mAb (green) and negative control (purple).
Red: Control Antigen (100ng); Purple: Antigen (10ng); Green: Antigen (50ng); Blue: Antigen (100ng);
Aurora A plays a role in cell cycle regulation during anaphase and/or telophase, in relation to the function of the centrosome/spindle pole region during chromosome segregation. Aurora A plays a key role during tumor development and progression and is overexpressed in many human cancers including breast, ovarian and colorectal. Aurora A is viewed as a potential target for anticancer drug treatment.Tissue specificity: Highly expressed in testis and weakly in skeletal muscle, thymus and spleen. Also highly expressed in colon, ovarian, prostate, neuroblastoma, breast and cervical cancer cell lines.
|References (references)||1. Cell Cycle. 2008 Nov 15;7(22):3525-33. |
2. Oncogene. 2008 Nov 20;27(51):6539-49.